• Adaptive Biotechnologies recently announced that its NGS-based clonoSEQ test for measurable residual disease was featured in 33 presentations, including a plenary session and 14 oral talks, at the 2026 ASCO and EHA meetings, underscoring its use across multiple myeloma, CLL, ALL, and lymphoma in both research and clinical care.
• An interesting angle for investors is how clonoSEQ’s FDA clearance, Medicare coverage, CE-mark under EU IVDR, and growing use as an MRD endpoint in interventional trials together reinforce its position as a widely adopted tool in hematologic oncology.
• We’ll now examine how clonoSEQ’s extensive ASCO and EHA presence, especially its MRD endpoint role, may influence Adaptive’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 12 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Adaptive Biotechnologies Investment Narrative Recap

To own Adaptive Biotechnologies, you need to believe clonoSEQ can anchor a large, recurring MRD testing franchise while the broader company moves closer to sustainable profitability. The ASCO and EHA data-heavy presence strengthens the near term catalyst around pharma trial adoption and clinical usage, but it does not materially change the biggest current risk of ongoing company wide losses and potential future funding needs if progress slows.

The most relevant recent announcement alongside ASCO and EHA is Adaptive’s May 5 update raising 2026 MRD revenue guidance to US$260 million to US$270 million. Together with clonoSEQ’s prominent role as an MRD endpoint at major meetings, this guidance ties the scientific validation story directly to near term revenue expectations, which sit at the center of both the upside catalyst and the concern about how quickly losses can narrow.

Yet, against this encouraging backdrop, investors should still weigh the risk that persistent net losses and cash burn could eventually force more dilution than many expect...

Adaptive Biotechnologies' narrative projects $451.6 million revenue and $70.4 million earnings by 2029. This requires 15.2% yearly revenue growth and a $120.1 million earnings increase from -$49.7 million today.

Uncover how Adaptive Biotechnologies' forecasts yield a $20.14 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already saw clonoSEQ’s momentum as a springboard to roughly US$447.1 million of revenue and positive earnings by 2029, so this new conference spotlight could either support that bullish view or prompt revisions, depending on how you think the growing trial and clinical use offsets ongoing cost and competition risks.

Explore 3 other fair value estimates on Adaptive Biotechnologies - why the stock might be worth just $20.14!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Adaptive Biotechnologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adaptive Biotechnologies' overall financial health at a glance.

No Opportunity In Adaptive Biotechnologies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.